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Abstract
Background: Agomelatine is a melatonergic receptor agonist and a 5HT2C receptor antagonist that has shown 
antidepressant efficacy. In order to analyze separately the effect of the two receptorial components, rats were 
chronically treated with agomelatine, melatonin (endogenous melatonergic agonist), or S32006 (5-HT2C antagonist), 
and then subjected to acute footshock-stress.
Results: Only chronic agomelatine, but not melatonin or S32006, completely prevented the stress-induced increase of 
glutamate release in the rat prefrontal/frontal cortex.
Conclusions: These results suggest a potential synergy between melatonergic and serotonergic pathways in the 
action of agomelatine.
Background
Despite the improved tolerability of newer antidepres-
sants such as the selective serotonin reuptake inhibitors
(SSRIs) [1-4] and the dual serotonin-norepinephrine
reuptake inhibitors (SNRIs), adverse events associated
with their use can influence adherence rates. There is an
unmet need for a better understanding of the mecha-
nisms and therapeutic management of depression, as well
as for treatments with improved efficacy and tolerability.
Indeed, both the pathophysiology of depression and the
exact mechanisms whereby antidepressants elicit a thera-
peutic response have not been fully explored. An increas-
ing body of evidence indicates that depression is
associated with a disruption of circadian rhythms, sug-
gesting that resetting of disrupted circadian rhythms may
play a pivotal role in the treatment of this condition [5-
11]. Agomelatine is a melatonergic receptor (MT1/MT2)
agonist [12] and 5HT2C receptor antagonist [13] that has
showed antidepressant efficacy in animal models [14-17]
and clinical trials [18-21].
Recent findings have shown that, in addition to the
changes induced in monoamine transmission, antide-
pressants may work by modulating glutamate release and
transmission in relevant limbic and cortical areas [22-24].
In this regard, we have previously found that different
chronic antidepressant treatments (including agomela-
tine) abolish the increase of depolarization-evoked gluta-
mate release, induced by acute footshock (FS)-stress,
from synaptosomes of prefrontal/frontal cortex (P/FC)
[25,26]. Here we studied the two separate components in
the mechanism of agomelatine, by treating rats chroni-
cally with either agomelatine, or melatonin (the endoge-
nous agonist of MT1/MT2 receptors), or S32006 (a
selective 5-HT2C antagonist), and then subjected the rats
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Page 2 of 4to FS-stress as above. Aim of the experiments was to
investigate whether one of the two receptorial compo-
nents was sufficient for the dampening action of agomel-
atine on stress-induced glutamate release, or both
components were necessary. We found that chronic treat-
ment with either melatonin or S32006 did not signifi-
cantly reduce the stress-induced glutamate release, while
chronic agomelatine treatment, as observed previously,
completely abolished the stress-induced glutamate
release, suggesting a potential synergy between MT1/
MT2- and 5-HT2C-dependent pathways in the action of
agomelatine.
Results
Depolarization-evoked release of glutamate from P/FC 
synaptosomes is increased after acute footshock stress
After chronic drug treatments, rats were subjected to
standard acute FS-stress protocol (see Methods) and,
immediately after the stress session, the synaptosomes
were purified from P/FC. The presynaptic release of
endogenous glutamate and GABA evoked by 15 mM KCl
were measured from synaptosomes in superfusion, as
done previously [22,25,26]. One way ANOVA showed
significant difference among groups (F4,30 = 6.757; p <
0.0005). Indeed, acute FS-stress increased depolariza-
tion-dependent release of endogenous glutamate from P/
FC synaptosomes (45.9%) and, as previously observed
with several different antidepressants [25,26], chronic
agomelatine treatment completely prevented the stress-
induced increase of glutamate release (Figure. 1). In the
previous work [26] we also observed that agomelatine, as
well as other antidepressants, did not modify glutamate
release from P/FC synaptosomes in non-stressed rats
(not shown here). For this reason agomelatine treatment
of non-stressed rats was not replicated here; similarly
melatonin or S32006 treatment of non-stressed rats was
not performed here. Having agomelatine per se no effect
on glutamate release in P/FC in the absence of stress,
there was no point in testing if either of the two other
compounds per se may modify glutamate release. As
shown in Figure 1, in rats treated with melatonin and
then stressed, the release of glutamate was similarly
increased as in stressed rats. In rats treated with S32006
(antagonist of 5-HT2C receptor) a trend for reduction of
stress-induced glutamate release was observed (-70%) but
the compound did not significantly dampen stress-
induced glutamate release. No significant changes in
GABA release were induced by either FS-stress or any of
the drugs. No effect of acute agomelatine treatment
(same dose) was found on FS-stress increased release of
endogenous glutamate.
Discussion and Conclusion
In this study we sought to dissect the action of different
receptorial components of agomelatine, with regard to
the action of this drug on stress-induced glutamate
release in P/FC. This was carried out by performing
chronic treatments with either melatonin or a selective 5-
HT2C receptor antagonist (S32006), both endowed with
receptorial affinity comparable with the affinity of ago-
melatine for the respective receptors. The present results,
showing that only agomelatine but not the two other
compounds significantly prevented the stress-induced
increase of glutamate release, suggest that the action of
agomelatine on glutamate release requires both recepto-
rial components. However, it is worth noting that while
glutamate release in melatonin-treated rats was virtually
indistinguishable from stressed rats, in rats treated with
S32006 a trend for reduction of release was observed (-
70% compared to stress group). It may be speculated that
enhancement of noradrenergic and dopaminergic trans-
mission induced by 5-HT2C receptor antagonism [13] in
cortical areas is a necessary modification for dampening
of glutamate release, similar to the outcome of treatments
with monoamine reuptake inhibitors, which also increase
monoamine neurotransmission with a different mecha-
nism [for a discussion see ref. [27,28]]. However, in the
case of agomelatine only the combination of melatonergic
agonism with 5-HT2C receptor antagonism seems to be
sufficient for full blockade of stress-induced glutamate
release. This is in turn suggestive of a possible synergy
between melatonin and 5-HT2C receptor-dependent
pathways in the action of this drug.
Figure 1 Chronic agomelatine treatment but not melatonin or 
S32006 reduced stress-induced increase of glutamate release in 
the rat P/FC. 15 mM KCl-evoked glutamate and GABA release in rats 
treated with vehicle (control), subjected to acute FS-stress (Stress), 
chronically treated with Agomelatine and then subjected to stress (Ag-
omelatine+Stress), S32006 and then subjected to stress 
(S32006+Stress) or Melatonin and then subjected to stress (Mela-
tonin+Stress). Data are expressed as means ± SEM. * p < 0.01, ** p < 
0.001 Newman Keuls post-hoc tests following One-way ANOVA (n = 6-
7 rats/group).
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lished by Papp et al. [17], showing that the antidepressive
effects of agomelatine in the chronic mild stress model of
depression depend on a combination of its melatonin
agonist and 5HT2C antagonist properties. Furthermore,
comparable results were also obtained in the learned
helplessness model of depression, where antidepressant
effect was observed with agomelatine, but not after treat-
ment with melatonin or the selective 5-HT2C antagonist
SB242084 [14]. In this line, recently it has been demon-
strated that the effects of chronic agomelatine on cell sur-
vival in hippocampus as well as on Brain Derived
Neurotrophic Factor (BDNF) expression maybe due to a
synergy between both properties of the drug [29,30].
Further studies, at the level of intracellular signaling
and of presynaptic machinery [22,31,25,26], will investi-
gate the suggested cross-talk between post-receptor
pathways in the action of agomelatine on glutamate
release.
Methods
Footshock stress procedure and drug treatments
Sprague-Dawley rats (170-200 gr) were purchased from
Charles River (Calco, Italy). All experimental procedures
were performed in accordance with the European Com-
munity Council Directive 86/609/EEC and Italian legisla-
tion on animal experimentation (Decreto Ministeriale
124/2003-A). Rats were chronically (14 days) treated with
agomelatine (40 mg/kg i.p.), melatonin (40 mg/kg i.p.),
S32006 (10 mg/kg i.p.), or vehicle (hydroxyethylcellulose,
1%, 1 ml/Kg, i.p.), administered at 5.00 pm (2 h before the
start of the dark cycle, 7 pm). The doses of agomelatine
and melatonin were selected based on their reported
activities in animal models of depression [17,14], and on
their effect on neurogenesis [29]. Similarly, the dose of
S32006 was chosen based on previous works showing
antidepressant activity on neurogenesis and BDNF
[29,30], as well as on its activity on 5-HT2c receptors in
vivo and on neurogenesis [32].
The FS-stress protocol was performed 16 h after the
last administration, essentially as reported in ref. 33 (40-
min FS-stress; 0.8 mA, 20 min total of actual shock with
random intershock length between 2-8 sec). The FS-
stress box was connected to a scrambler controller (LE
100-26, Panlab) that delivers intermittent shocks to the
metallic floor. Sham-stressed rats (controls) were kept in
the stress apparatus without delivering of shocks. Rats
were killed immediately after FS-stress and P/FC were
quickly dissected on ice and processed as reported below.
Preparation of purified synaptosomes for glutamate/GABA 
release
Purified synaptic terminals (synaptosomes) were pre-
pared by centrifugation on Percoll gradients [34,22] from
fresh brain tissue, and resuspended in physiological
medium with the following composition (mM): NaCl,
125; KCl, 3; MgSO4, 1.2; CaCl2, 1.2; NaH2PO4, 1;
NaHCO3, 22; glucose, 10 (aeration with 95% O2 and 5%
CO2); pH 7.2-7.4.
Glutamate and GABA release experiments
Aliquots of the synaptosomal suspensions (about 100 μg
protein) were layered on microporous filters at the bot-
tom of a set of parallel superfusion chambers maintained
at 37°C [35,36]. Superfusion was started at a rate of 0.5
ml/min with standard medium aerated with 95% O2 and
5% CO2. After 36 min of superfusion, to equilibrate the
system, samples were collected according to the following
scheme: two 3-min samples (t = 36-39 min and t = 45-48
min; basal outflow) before and after one 6-min sample (t
= 39-45 min; stimulus-evoked release). A 90-sec period of
stimulation was applied at t = 39 min, after the first sam-
ple has been collected. Stimulation of synaptosomes was
performed with 15 mM KCl, substituting for equimolar
concentration of NaCl. Fractions collected were analysed
for endogenous glutamate and GABA content. Amino
acid release was expressed as nmol/mg of protein. The
stimulus-evoked overflow was estimated by subtracting
transmitter content of the two 3-min samples (basal out-
flow) from release evoked in the 6-min sample collected
during and after the depolarization pulse (stimulus-
evoked release). Effects of drug treatments were evalu-
ated by comparing the stimulus-evoked overflow in drug-
treated animals vs. that calculated in vehicle-treated rats.
Appropriate controls were always run in parallel. Endoge-
nous glutamate and GABA were measured by high per-
formance liquid chromatography analysis [22].
Statistical analysis
One-way analysis of variance (ANOVA) was used for the
analysis of glutamate release followed by post-hoc group
comparisons with Newman Keuls test. Statistical analysis
of the data was carried out using GraphPad Prism4
(GraphPad Software Inc., USA). For all analyses a value of
p < 0.05 was considered statistically significant.
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